Showing posts with label Biotechnology. Show all posts
Showing posts with label Biotechnology. Show all posts

Thursday, September 17, 2009

Survey Concludes Telaprevir a Winner for HCV Genotype 1 | Hepatitis Central News, Updates and Commentary

I did mention in my earlier blog about this drug and one person did (Dawn - Blog Name) mention she was happy about the info. I am sure the following update will help her. All the best...(Dawn, U can mail me at dr.umesh1969@gmail.com-if u find this info useful). I am happy something I did blog and that helped a needy & this encourages me to do spend more time with my blog.....

Survey Concludes Telaprevir a Winner for HCV Genotype 1 | Hepatitis Central News, Updates and Commentary

Shared via AddThis

FDA Okays Vaccines for 2009 H1N1 Influenza Virus !

At last one can breathe a sigh of relief from the H1N1 pandemic.....


FDA's approval of the Vaccine for H1N1.........


News: FDA Okays Vaccines for 2009 H1N1 Influenza Virus.

Shared via AddThis

Tuesday, September 15, 2009

Tuberculosis Patients Can Reduce Transmissability By Inhaling Interferon Through A Nebulizer

As for as my knowledge goes "Interferons" - (glycoproteins - natural cell-signaling proteins produced by the cells of the immune system of most vertebrates in response to challenges such as viruses, parasites and tumor cells).

1.  assist the immune response by inhibiting viral replication within host cells, activating natural killer cells and macrophages, increasing antigen presentation to T lymphocytes.

2. increasing the resistance of host cells to viral infection.

And are said to possess the antiviral and antitumour activity.   

But this finding is really interesting.................."Tuberculosis Patients Can Reduce Transmissability By Inhaling Interferon Through A Nebulizer

Shared via AddThis

Tigecycline- as antimalarial drug ?


                As for my knowledge goes,  'Tigecycline'  is being used  as  drug for the antibiotic resistant strain 'Staphylococcus aureus'.  And this drug belongs to the class of "glycylcyclines" (similar to tetracyclines : central four-ring carbocyclic skeleton).  The broad spectrum activity is attributed to the  D-9 position substitution. It is a bacteriostatic and acts by the inhibition of protein synthesis. It has been found to be active against both Gram positive and Gram negative bacterii. 

Now thanx to the researchers from the Medical University of Vienna, Austria, who have achieved something interesting feat, i.e.,  Tigecycline has significant antimalarial activity on its own and may also be effective against multi drug-resistant malaria when administered in combination with traditional antimalarial drugs

Increasing resistance of Plasmodium falciparum to existing drugs has resulted in the search for new antimalarial therapies and I congratulate the team for this important achievement.  More interestingly the drug is 6 times more active against P. falciparum than doxycycline. As the drug itself is an established one,  its one more addition to the serendepity list. Congrats the team...

Ref : http://www.asm.org/index.php?option=com_content&view=article&id=91042


Monday, September 14, 2009

Lurasidone - positive results from phase 3 clinical trials !

I  read about this compound few months back, that it is one of  "atypical antipsychotic" drugs that are being tried and this drug has shown promising results in the phase II and is being studied clinically for phase III  by a Japanese company.  


As per the claims by the company 'Lurasidone,  blocks D2- and 5-HT2A-receptors and the advantage is it causes less extrapyramidal side effects than current antipsychotics.


Yes the phase 3 results are really interesting,  with Lurasidone 40 and 120 mg, taken once-daily, demonstrated significantly greater improvement versus placebo on the primary efficacy measure. A total of 53% of patients on lurasidone 40 mg/day and 47% of patients on lurasidone 120 mg/day demonstrated a 30% or more improvement on the PANSS total score from baseline versus 38% on placebo. Lurasidone was also well-tolerated with an overall discontinuation rate similar to placebo (40% vs. 39% placebo) and few adverse event-related discontinuations (9% for both the overall lurasidone group and placebo). Adverse events seen in the trial were generally mild.

Congrats for this achievement. 

Ref : http://dsp-america.com/pdf/news/LurasidonePh3Results.pdf

Tigecycline- as antimalarial drug ?


                As for my knowledge goes,  'Tigecycline'  is being used  as  drug for the antibiotic resistant strain 'Staphylococcus aureus'.  And this drug belongs to the class of "glycylcyclines" (similar to tetracyclines : central four-ring carbocyclic skeleton).  The broad spectrum activity is attributed to the  D-9 position substitution. It is a bacteriostatic and acts by the inhibition of protein synthesis. It has been found to be active against both Gram positive and Gram negative bacterii. 

Now thanx to the researchers from the Medical University of Vienna, Austria, who have achieved something interesting feat, i.e.,  Tigecycline has significant antimalarial activity on its own and may also be effective against multi drug-resistant malaria when administered in combination with traditional antimalarial drugs

Increasing resistance of Plasmodium falciparum to existing drugs has resulted in the search for new antimalarial therapies and I congratulate the team for this important achievement.  More interestingly the drug is 6 times more active against P. falciparum than doxycycline. As the drug itself is an established one,  its one more addition to the serendepity list. Congrats the team...

Ref : http://www.asm.org/index.php?option=com_content&view=article&id=91042

Saturday, September 12, 2009

A single dose vaccine for Swine flu !.....

I am reading anything and everything about this H1N1, since it started in Mexico and there were so many different names (many names  like - swine flu !, Mexican flu, ....).   The deadly virus has caused panic in each and every country, where there are reports of infection of H1N1.  The real concern is the use of antibiotics and the real black market  for Tamiflu and so many falsely claimed  drugs. Now thanx to Dr. Russell Basser and group who have found that a single 15-µg dose of 2009 H1N1 vaccine was immunogenic in adults, with mild-to-moderate vaccine-associated reactions. Congrats for for this important  achievement. 

A (H1N1) 2009 virus is responsible for the first influenza pandemic in 41 years. This itself shows how important the vaccine is.  The results are really interesting and as per the claim by the researchers : by day 21 after vaccination,  antibody titers of 1:40 or more were observed in 96.7%  those who received the 15-µg dose  and 93.3% who received the 30-µg dose. No deaths, serious adverse events, or adverse events of special interest were reported. Local discomfort (e.g., injection-site tenderness or pain) was reported by 46.3% of subjects, and systemic symptoms (e.g., headache) by 45.0% of subjects. Nearly all events were mild to moderate in intensity.  

Hope the efforts by the Australian drug maker CSL, Ltd. has yielded a novel vaccine that could take care of the H1N1 pandemic. Congrats once again for this achievement. 

Ref : http://content.nejm.org/cgi/content/full/NEJMoa0907413


Sunday, September 6, 2009

Discovery Of Natural Odors- a new way to develop cheaper mosquito repellents !..

Entomologists at the University of California, Riverside (Anandasankar Ray, an assistant professor in the Department of Entomology, and Stephanie Turner, his graduate student)  working on fruit flies in the lab have discovered a novel class of compounds that could pave the way for developing inexpensive and safe mosquito repellents for combating West Nile virus and other deadly tropica. 

The basis for the 'invention' though looks simple, but this finding is of great importance. As for my knowledge goes most of the mosquito repellents are cyclohalothrins, which are a costly affair to prepare [as a synthetic chemist,  I know how difficult its to prepare cyclohalothrins (pyrethroids)  e.g., Allethrin & Permethrin. When I was working in Rallis India Limited, one of my senior colleague was working on Permethrin and I know how difficult to introduce the halo group that too by using florochlorocarbons CFCs (banned chemicals !)]. Congrats Anandsankar Ray, for this interesting achievement. 

When fruit flies undergo stress, they emit carbon dioxide (CO2) that serves as a warning to other fruit flies that danger or predators could be nearby. The fruit flies are able to detect the CO2 and escape because their antennae are equipped with specialized neurons that are sensitive to the gas.

But fruits and other important food sources for fruit flies also emit CO2 as a by-product of respiration and ripening. If the innate response of the fruit fly is to avoid CO2, how then does it find its way to these foods?. The researchers have have identified a new class of odorants – chemical compounds with smells – present in ripening fruit that prevent the CO2-sensitive neurons in the antennae from functioning. In particular two odors, hexanol and 2,3- butanedione, are strong inhibitors of the CO2-sensitive neurons in the fruit fly.

CO2 emitted in human breath is the main attractant for the Culex mosquito to find people, aiding the transmission of these deadly diseases," Ray said. In their  experiments they  identified hexanol, and a related odor, butanal, as strong inhibitors of CO2-sensitive neurons in Culex mosquitoes. These compounds can now be used to guide research in developing novel repellents and masking agents that are economical and environmentally safe methods to block mosquitoes.
Those interested can listen to Anandsankar

Fruits better than prviously thought !.......

Polyphenol content in fruits usually refers to extractable polyphenols, but a Spanish scientist working at the Institute of Food Research in Norwich analysed apple, peach and nectarine. She found that nonextractable polyphenol content is up to five times higher than extractable compounds. Its really interesting and that might be the reason why our forefathers used to insist to eat whole fruits (though they might not have studied so exhaustively... !).  

The interesting findings like,  "polyphenols need to be treated with acid to extract them from the cell walls of fruit in the lab" will help at least now onwards to collect all the useful polyphenols (proanthocyanidins, ellagic acid and catechin)  which without this new findings might have gone as waste.  Dr Paul Kroon from IFR explains: “In the human body these compounds will be fermented by bacteria in the colon, creating metabolites that may be beneficial, for example with antioxidant activity. 

Hope these  nonextractable polyphenols, (which mostly escape analysis and are not usually considered in nutritional studies),  will play a major part of bioactive compounds in the diet  in the days to come. Congrats Professor Saura-Calixto, for this  achievement.....


Sunday, August 23, 2009

Wearable Artificial Kidney good bye to dialysis !

I have seen people who had kidney failure and how its difficult to get dailysis & to mentain the sterile conditions to avoid infections. Now thanx to a group of researchers from David Geffen School of Medicine at UCLA,  who have come up with a novel idea of developing wearable artificial kidney!. 
As per the claim by the researchers, the device—essentially a miniaturized dialysis machine, worn as a belt—weighs about 10 pounds and is powered by two nine-volt batteries. Patients don't need to be hooked up to a full-size dialysis machine, they are free to walk, work, or sleep while undergoing continuous, gentle dialysis that more closely approximates normal kidney function. Despite enduring long hours on dialysis every week—with major limitations in activities, diet, and other areas of life—dialysis patients face high rates of hospitalization and death and more over its a costly affair too. 
The Wearable Artificial Kidney is successful in preliminary tests, including two studies in dialysis patients. The new study provides important information on the technical details that made these promising results possible. Though further studies like 'long-term effect' has to be established its a great achievement  and hope the researchers will succeed in their endeavor....
Congrats,  Victor Gura et.al., 

Saturday, August 1, 2009

New journal devoted to gene therapy...

As for as my knowledge goes there was no exclusive journal totally devoted to gene therapy until last year. Yeah its really interesting to to see "The Gene Therapy Review" a journal totally devoted to gene therapy. In my opinion it is an important move and was the urgent need of the hour. Now the fields like antisense drugs & gene therapy will get its due importance and hope in the days to come, will bring together all those people to share and gain the knowledge..... Those interested can follow the blog also.....

URL : http://www.genetherapyreview.com/index.php

Blog : http://www.genetherapyreview.com/gene-therapy-blog.html




Sunday, June 28, 2009

Masitinib - a relief for arthritis patients ....


I know the sufferings of arthritis patients closely, (as my mother-in-law is having the problem) it makes patients' life miserable. Though there are a few drugs for the treatment, but are inadequate for patients suffering from active rheumatoid arthritis (RA) especially for those unresponsive to disease-modifying antirheumatic drugs (DMARDs), new and improved medication is need of the hour. In that aspect clinical trials of Mastineb, 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl] amino] phenyl]benzamide carried out by Alain Moussey et. al., is of great importance.
The study evaluates the safety and efficacy of Masitinib, a potent and selective protein tyrosine kinase inhibitor of c-KIT, in the monotherapy treatment of DMARD-refractory RA.
We also know that, the orally bioavailable mesylate salt of masatinib, a multi-targeted protein tyrosine kinase inhibitor with potential antineoplastic activity selectively binds to and inhibits both the wild-type and mutated forms of the stem cell factor receptor (c-Kit; SCFR); platelet-derived growth factor receptor (PDGFR); fibroblast growth factor receptor 3 (FGFR3); and, to a lesser extent, focal adhesion kinase (FAK). As a consequence, tumor cell proliferation may be inhibited in cancer cell types that overexpress these receptor tyrosine kinases (RTKs), clinical trials also reported.
As per the conclusions by the authors, treatment with masitinib improved DMARD-refractory active RA. Following an initial high incidence of mostly mild to moderate side effects during the first 12 weeks of treatment, masitinib appears to be generally well tolerated. This, together with evidence of a sustainable efficacy response, suggests that masitinib is suitable for long-term treatment regimens. Since this was the first study of masitinib in a nononcologic pathology, the relatively high patient withdrawal rate observed can be partly attributed to a highly cautious response to adverse events. There is sufficient compelling evidence to warrant further placebo-controlled investigation. Congrats for the group...

Sunday, June 21, 2009

Antisense drug in combination with paclitaxel for prostate cancer..

I think when I was doing some reference work for my research in 1996, I read about this drug (taxol) [In 1994 the total synthesis has been achieved by Robert Holton of Florida University. He did spend 12 years to achieve the total synthesis because of the assymmtery involved in it [It was after 40 years' after the first exctract from the tree Pacific yew (Taxus brevifolia) has shown anticancer activity and the key ingrediant identified was taxiol]. A diterpenoid, with androgen (a male hormone) blockade chemotherapy has played important role in the treatment of cancer.

Prostate cancer is the second most frequently diagnosed cancer in men after skin cancer. It is estimated there will be 218,890 new cases diagnosed in the U.S. this year(2009). Around 1 in 6 men will develop prostate cancer, a third to a half of whom will recur after local treatment and risk progression to metastatic prostate cancer. Metastatic disease invariably progresses to hormone refractory or castrate resistantprostate cancer (CRPC) if given enough time.

Prostate tumours are initially androgen (male sex hormone) dependent, and can be treated with androgen ablation therapy, however once the disease progresses to its most dangerous and aggressive form, CRPC, treatment options are limited and prognosis is poor. Treatment options depend on disease severity and include radiation and chemotherapy, which are designed to induce programmed cell death (apoptosis) of tumour cells. There is a pressing need for the development of new treatment options.

More interesting and significant results have been achieved by an Australian company (Antisense Therapeutics). i.e., in combination with taxol, antisense drug ATL1101 has yielded good results. ATL1101 is a second generation antisense inhibitor of the insulin-like growth factor-I receptor (IGF-IR) which as reported previously suppressed the growth of human prostate tumors in an animal model of prostate cancer, and slowed down transition to CRPC when used as a single agent.

The research is of great importance because of the fact that in cell culture experiments, the amount of Paclitaxel required to induce tumor cell apoptosis (cell death) was significantly reduced when used in combination with ATL1101. This ability to 'sensitize' tumor cells to the cytotoxic effects of Paclitaxel affirms ATL1101's potential as a chemo-sensitizing agent to be used in combination with existing prostate treatments to improve the outcomes for patients.

I did work for some of the intermediates (ologonucleotides) for ISIS (contract research) and am excited to see that this company has tie up with ISIS. In my opinion as ISIS , is an established company in this field of research, hope soon there will be relief for those patients for whom CRPC, treatment options are limited and prognosis is poor....

Ref: http://www.antisense.com.au/!upload_files%5Cattachment%5Casx%2009%2018%20June%202009_ATL1101.pdf



Sunday, June 7, 2009

Telaprevir for Hepatitis C, soooon...


We did know that Telaprevir (VX-950), is a member of a class of antiviral drugs known as 'Protease Inhibitors' was an experimental treatment for Hepatitis and two companies Vertex and Johnson & Johnson jointly developed and phase II clinical trials were being done. Now thanx, to Dr. Ira M. Jacobson chief of the Division of Gastroenterology and Hepatology at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, and the Vincent Astor Distinguished Professor of Clinical Medicine at Weill Cornell Medical College, who has come up with the results of Phase IIb clinical trial.

Th results are really encouraging and as per the author, "the findings point the way to a new era in the treatment of hepatitis C". The most significant part of the research lies in the fact that, by adding Telaprevir the treatment was more effective and quicker and there by reducing the therapy to half (from 48 weeks to 24 weeks).

Results showed that 67 percent of patients taking telaprevir in combination with standard therapy for 12 weeks followed by standard therapy alone for 36 weeks were cured; and 61 percent of those taking telaprevir in combination with standard therapy for 12 weeks followed by standard therapy alone for 12 weeks were cured. This is compared to 41 percent cure rate in the 48-week control group. And more over the study also showed that the percentage of patients who relapsed in the 24-week and 48-week telaprevir-based groups (2 percent and 6 percent, respectively) was much lower than the control group (23 percent). Also the authors found that it can be used alongwith Ribavirin, for those with HIV & Hepatitis C. Congratulations for this achievement. Phase III clinical trials are currently underway at the NewYork-Presbyterian/Weill Cornell and centers worldwide will attempt to confirm the results, potentially leading to FDA approval of telaprevir and hope there will be a relief to the sufferers very soooon......

Ref : http://news.med.cornell.edu/wcmc/wcmc_2009/06_04_09.shtml

Saturday, June 6, 2009

Pazopanib for aggressive thyroid cancer.

There were lots of research groups involved in testing Pazopanib for diverse anticancer activity like "epithelial ovarian cancer, non small cell lung cancer and GSK was the key researcher and did try the phase III clinical trials in other cancer types, in Sept., 2008. Now thanx, Dr. Keith Bible, a medical oncologist and researcher who led the multicenter clinical trial funded by the National Cancer Institute, for this significant findings - cancer in about two-thirds of 37 patients with aggressive differentiated thyroid cancer treated with the drug pazopanib either stopped growing, or quickly shrank. And as per the conclusions : one-third of patients achieved sustained and dramatic benefit from pazopanib, while another one-third experienced stabilization of their cancer or some tumor shrinkage. The remaining one-third of patients did not benefit from the drug. The agent was also well tolerated by the majority of patients. Though further studies like - drug's effect on overall survival still to be established its a good beginning.


As per the authors conclusion majority of the patients with thyroid cancer respond well to surgery and to follow-up treatment with radioiodine; even if the cancer recurs and spreads, the disease progresses slowly in most patients. Many patients do well for a long time without the need of additional therapy. However, about 5 percent of these patients experience rapidly progressing life-threatening disease that is insensitive to radioiodine and other treatment approaches and for them this treatment will be a good one, the researchers claim. Congrats Dr. Bible and group..

Ref : http://www.mayoclinic.org/news2009-rst/5272.html


Glutamine for stomach ulcer ?

We know that Glutamine is the most abundant naturally occurring, non essential amino acid in the human body and one of the few amino acids which directly crosses the blood brain barrier. In the body it is found circulating in the blood as well as stored in the skeletal muscles. It becomes conditionally essential (requiring intake from food or supplements) in states of illness or injury.

Dietary sources of L-glutamine include beef, chicken, fish, eggs, milk, dairy products, wheat, cabbage, beets, beans, spinach, and parsley. Small amounts of free L-glutamine are also found in vegetable juices and fermented foods, such as miso.

In one of my earlier blog, I did mention that broccoli, has been found useful against the H. pylori infection, now its the turn of Glutamine-that has been found useful against the infection. Dr. Susan Hagen, Associate Director of Research in the Department of Surgery at BIDMC and Associate Professor of Surgery at Harvard Medical School and group has found that extra glutamine in the diet could protect against gastric damage caused by H. pylori.

Gastric damage develops when the bacteria weakens the stomach's protective mucous coating, damages cells and elicits a robust immune response that is ineffective at ridding the infection. Eventually, she notes, years of infection result in a combination of persistent gastritis, cell damage and an environment conducive to cancer development. Dr. Hagen and her co-authors had previously shown that glutamine protects against cell death from H. pylori-produced ammonia. And further studies revealed that, the damaging effects of ammonia on gastric cells could be reversed completely by the administration of L-glutamine," explains Hagen. "The amino acid stimulated ammonia detoxification in the stomach - as it does in the liver - so that the effective concentration of ammonia was reduced, thereby blocking cell damage', which encouraged the group to hypothesize that a similar mechanism might be at work in the intact stomach infected with H. pylori.

The results are encouraging and are of great importance, because of the fact that the animals exhibited increased expression of three cytokines - interleukin 4, interleukin 10 and transforming growth factor-alpha mRNA. According to the authors these all play an important role in the stomach's ability to protect against damaging effects resulting from other responses to H. pylori infection. And more interestingly-glutamine supplementation may be an alternative therapy for reducing the severity of infection. Thus ptoviding a relief to the patients suffering from H.Pylori. H. pylori bacteria infect more than half of the world's population and were recently identified as a Group 1 carcinogen by the WHO. Hope this inexpensive, easy-to-use treatment could be used to modify the damaging effects of H. pylori infection inthe near future.
Congrats Dr. Susuan and group. ....

Ref : http://www.bidmc.org/News/InResearch/2009/May/StomachUlcers.aspx


Wednesday, June 3, 2009

Mechanism of Antibiotic Resistance Explained !

We all know that the introduction of antibiotics as drugs in the treatment of bacterial infections in the post-WWII years was a revolutionized medicine, and dramatically improved the health condition on a global scale. 60 years later now, the growing antibiotic resistance among pathogens has heavily depleted the arsenal of entailed effective antibiotic drugs and especially in the case of TB, combination of 4 drugs is being used and don't know what happens ?. Now thanx to Prof. Måns Ehrenberg for his novel discovery i.e., inhibiting the "drug efflux pumps" in bacteria, which function as their defence mechanisms against antibiotics, can mask the effect of mutations that have led to resistance in the form of low-affinity drug binding to target molecules in the cell. This is shown by researchers at Uppsala University in a new study that can provide clues to how the development of resistance to antibiotics in bacteria can be delayed.

This new study, experimentally and theoretically explained how the inhibition of these drug efflux pumps can completely mask the resistance effect of mutations that reduce the affinity of antibiotics to their target molecules in the bacteria cell. The effect of the mutations is entirely hidden when the pumps are unable to remove the antibiotic sufficiently quickly in relation to the dilution of the antibiotic through cell growth and cell division.

A new way for drug discovery....

Ref : http://www.pnas.org/content/early/2009/04/30/0811514106.abstract?sid=4175ffe7-b04b-4fc3-9270-af9a9bd5d953

Tuesday, June 2, 2009

Auranofin an arthritis drug as new antibiotic?

Traces of mineral selenium is found in a number of proteins in both bacterial cells and human cells called selenoproteins. Associate Professor William Self's research shows that interrupting the way selenoproteins are made can halt the growth of the super bug Clostridium difficile and Treponema denticola, a major contributor to gum disease.

Infections of Clostridium difficile (C-diff) lead to a wide range of illnesses ranging from severe diarrhea to colitis, which can cause death. It's a life-threatening problem in hospitals and nursing homes worldwide, and the number of cases is on the rise. There are an estimated 500,000 cases per year in the US alone. Between 15,000 to 20,000 people die each year while infected with this superbug. Treponema denticola is one of leading causes of gum disease and costs individuals thousands of dollars in dental care each year.

The significance of the research lies in the fact that, the gold drug Auranofin used to treat arthritis, impacted selenium's metabolism process. The chemical reaction changes the selenium, which prevents bacteria from using it to grow. Auranofin is an FDA-approved gold salt compound that is used to control inflammation and is already known to inhibit the activity of certain selenoproteins. Since certain bacteria, such as C. difficile, require selenoproteins for energy metabolism, the drug acts as a potent antimicrobial halting the growth of the bacteria. The initial studies with C. difficile led to studies with T. denticola, known for several years to require selenium for growth. While testing the gold salt, Self's group also uncovered another surprise; the stannous salts found in many antimicrobial toothpastes in the form of stannous fluoride also inhibited the synthesis of selenoproteins. Previous independent research had already established that stannous salts are more effective at preventing tooth decay and inhibiting growth of T. denticola, but the mechanism of this inhibition of growth was not yet known. These findings could lead to new approaches to preventing gum disease. The out come of the research is really interesting because no one in the earlier days thought of this innovative idea, i.e., to block the metabolism of selenium before as a therapeutic approach. And also this may through some light how "gold salt works for arthritis". Congrats Prof. Self and co workers...

Ref :http://www.springerlink.com/content/g6725k414863446q/?p=1f9d7cac7a4e4867af336327382c16bd&pi=4

Tuesday, May 26, 2009

Aerosol delivery of antibiotics via nanoparticles !

These days we are hearing lots of news about "nano", I would say anything and everything is nano, now its the turn of drug delivery that too as "aerosol" form!. Though there were lots of research groups trying to do the nanoway, I think this is something really interesting. Carolyn L. Cannon, M.D., Ph.D. from Washington University School of Medicine, and colleagues from the Center for Silver Therapeutics Research at the University of Akron in OH investigated the efficacy of nanoparticle-encapsulated silver-based antibiotics for treating pulmonary infections in a mouse model of pneumonia.

Treatment with antibiotic-laden nanoparticles effectively eliminated respiratory infections in mice that had been inoculated with Pseudomona aeroginosa, a common bacterial species that often infects the respiratory tract in humans, particularly immunocompromised patients, ventilated patients or those with cystic fibrosis. Infected mice that inhaled aerosolized nanoparticles encapsulating silver carbene complexes (SCCs), a novel class of silver-based antimicrobials with broad-spectrum activity, showed a significant survival advantage over the control mice that received nanoparticles without the SCCs. The results are really interesting and even the half the dose is sufficient. Toxicity results are still to be done, however this is a good beginning and hope they will come up with interesting results in the near future...

Ref :http://www.thoracic.org/sections/publications/press-releases/conference/articles/2009/abstracts-and-press-releases/cannon.pdf

Sunday, May 24, 2009

New Vaccine for TB...!

We are aware that TB has become one of the most dangerous disease (more than two billion people are infected with tuberculosis – approximately one out of every three people on the planet – and 1.8 million die annually from the disease). And also the strain is getting resistance to the single drug and a combination of Rifampicin, Ethumbutol, Isoniazid and Streptomycin a combo of 4 drugs is being used as treatment. And as per the saying "Prevention is better than Cure", a new vaccine is urgently needed, as BCG is currently the only available vaccine against TB, and provides only variable protection against pulmonary tuberculosis, which accounts for most of the worldwide disease burden. Now thanx to Dr Helen McShane, a Wellcome Trust Senior Clinical Research Fellow, working with Dr Sarah Gilbert, a Reader in Vaccinology, and Professor Adrian Hill, a Wellcome Trust Principal Research Fellow- who together achieved a milestone in developing the vaccine and it has entered Phase IIb proof-of-concept clinical trials, making it the first TB candidate vaccine for more than 80 years to get to this advanced stage of clinical trials in infants. There is still a long road ahead, but this marks an important milestone toward the goal of a more effective TB vaccine. First I congratulate for this milestone and wish them all the success in their attempt.

Ref : http://www.ox.ac.uk/media/news_stories/2009/090423.html